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Abstract: The expression of certain endothelial cell adhesion molecules is increased   during 
endothelial dysfunction or inflammatory activation. This has led to the concept of using microbub-
bles for targeted molecular imaging or drug delivery. In this approach, microbubbles with a 
specific ligand to receptors expressed at the site of specific diseases are constructed. The present 
study aimed to engineer a novel type of bio-functionalized microbubbles (vascular cell adhe-
sion molecule 1 [VCAM-1]-targeted microbubbles), and determine whether VCAM-1-targeted 
microbubbles exhibit specific adhesion to lipopolysaccharide (LPS)-activated endothelial cells. 
Our data showed that VCAM-1 expression was significantly upregulated in both LPS-activated 
endothelial cells in vitro and endothelium in a rat atherosclerosis model in vivo. Targeted 
microbubbles were designed by conjugating anti-VCAM-1 monoclonal antibodies to the shell 
of microbubbles using biotin–avidin bridging chemistry methods. Microbubble adhesion 
to endothelial cells was assessed in a flow chamber at two shear stress conditions   (6.3 and 
10.4 dynes/cm2). Our data showed that microbubble adhesion depends on both the surface anti-
VCAM-1 antibody densities and the exposed shear stresses. Adhesion of VCAM-1-targeted 
microbubbles onto LPS-activated endothelial cells increased with the surface antibody densities, 
and decreased with the exposed shear stresses. These findings showed that the specific ligand-
carrying microbubbles have considerable potential in targeted ultrasound molecular imaging 
or ultrasound-assisted drug/gene delivery applications.
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Introduction
Ultrasound contrast agents composed of gas-filled microbubbles with diameters gener-
ally ranging from 2 to 8 µm have been in clinical use for many years.1,2 These agents can 
improve accuracy and imaging contrast for targeted sites of interest during ultrasound 
imaging. In the last 10 years, several site-targeted microbubbles have been developed, 
and have been used for molecular and cellular imaging in vitro and in vivo,3,4 as well 
as for ultrasound-assisted drug/gene delivery and triggered release.5–7
The expression of endothelial cell adhesion molecules known to play an important 
role in leukocyte recruitment (ie, VCAM-1, E-selectin, P-selectin, and ICAM-1), are 
often increased at the sites of pathological inflammation.8 This observation has led to a 
strong interest in the development of targeted delivery strategies that exploit the increased 
expression of endothelial cell adhesion molecules to achieve selective delivery to the 
sites of interest. VCAM-1, expressed by inflammatory endothelial cells, participates in International Journal of Nanomedicine 2011:6
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Figure 1 schematic illustration for surface bio-functionalization to form VcAM-1 
targeted microbubbles through a biotin–streptavidin bridging chemistry method.
Abbreviation: VcAM-1, vascular cell adhesion molecule 1.
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leukocyte rolling and adhesion primarily by interacting with its 
counterligand α4β1 on monocytes and lymphocytes. VCAM-1 
on the vessel endothelial surface also plays an important role 
in atherosclerosis development.   Atherosclerosis is regarded as 
a chronic inflammatory disease, and endothelial dysfunction 
is one of the key events in the pathogenesis of atherosclerosis. 
Previous studies have been reported in which overexpres-
sion of VCAM-1 and/or other cell adhesion molecules has 
been associated with endothelial cell dysfunction and ath-
erosclerosis progression.9,10 This suggests that VCAM-1 is 
an ideal target for microbubble targeted delivery.
We hypothesized that targeted microbubbles could 
be prepared by coupling the ligands of endothelial cell 
adhesion molecules onto the microbubble surface. The 
  bio-functionalized microbubbles would then bind to the 
specific endothelial cell adhesion molecules whose expres-
sions were upregulated on the endothelial cell surfaces, and 
be retained in the inflamed endothelium. It was necessary to 
profile the bio-functionalized microbubble adhesion in vitro 
under flow conditions. A parallel plate flow chamber system 
has been widely used to study the adhesion and interaction of 
neutrophils, platelet, and cancer cells with endothelial cells 
under flow conditions.11–13
In this study, a parallel flow chamber system was used to 
investigate the adhesion of VCAM-1-targeted microbubbles 
to an endothelial cell monolayer under controlled shear 
conditions. The process of adhesion was also examined, 
which will be helpful in the prediction of in vivo adhesion 
behavior of targeted microbubbles, as well as their future 
clinical applications.
Materials and methods
Materials
Cell culture medium RPMI 1640 and newborn calf serum 
(NCS) were purchased from Gibco (Grand Island, NY). 
Lipopolysaccharide (LPS) (from Escherichia coli 055:B5), 
trypsin, HAT (hypoxanthine, aminopterin, and thymidine) 
supplement, polyoxyethylene-40 (PEG-40) stearate, peni-
cillin and streptomycin were obtained from Sigma-Aldrich 
(St Louis, MO). 2-[4-(2-Hydroxyethyl)-1-piperazine]- 
ethanesulfonic acid (HEPES) was supplied by Amresco 
(Cleveland, OH). Distearoylphosphatidylcholine (DSPC) and 
distearoylphosphatidylethano- lamine-biotin (DSPE-biotin) 
were from Avanti Polar Lipids (Alabaster, AL). Biotinylated 
anti-VCAM-1 monoclonal antibody, streptavidin, and phyco-
erythrin-labeled streptavidin (PE-streptavidin) were obtained 
from BioLegend (San Diego, CA). Rabbit   anti-human 
VCAM-1 antibody and goat anti-rabbit   secondary antibody 
were from ZSGB-BIO (Beijing, China). All other chemicals 
used were of analytic grade without further purification, if 
not stated otherwise.
Preparation of bio-functionalized  
ultrasound microbubbles
Microbubbles with monoclonal antibodies against VCAM-1 
conjugated to their surfaces were constructed using a multi-
step biotin–avidin bridging chemistry method described 
previously with some modifications.3,14 Briefly, the DSPC 
and DSPE-biotin were dispersed along with the surfactant 
PEG-40 stearate in chloroform solvent. The solvent was 
evaporated at 58°C, and replaced with a phosphate buffer 
saline (PBS). The mixture was sonicated for 30 seconds in 
the presence of perfluoropropane (C3F8) gas. The sonication 
dispersed the perfluoropropane gas in the PBS solution dur-
ing the microbubble formation. Static flotation was used to 
remove unincorporated lipids from microbubbles by triple 
washing with PBS. The biotinylated microbubbles were incu-
bated with PE-streptavidin in PBS for 60 minutes at 4°C, and 
the unbound PE-streptavidin was removed by static flotation 
as described above. The PE-streptavidin coated biotinylated 
microbubbles were then incubated with biotinylated anti-
VCAM-1 monoclonal antibody or isotype control biotiny-
lated antibody (IgG) for 60 minutes at 4°C, and the unbound 
antibody was removed by static flotation, using triple washing 
with PBS. Targeted microbubbles were thus prepared with 
biotinylated anti-VCAM-1 monoclonal antibody coupled to 
the phospholipid monolayer of the microbubble shell through 
a biotin–streptavidin bridge (Figure 1).
Biophysical characterization  
of microbubbles
To observe the morphology of the prepared microbubbles, 3,3′-
dioctadecyloxacarbocyanine perchlorate (DiO) (Molecular International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Probes, Eugene, OR), a cell membrane green fluorescent 
probe, was used to label the shell of microbubbles. Microbub-
ble suspension (500 µL) was incubated with 1 mL DiO solu-
tion (10 µM) for 20–30 minutes, followed by triple washing 
in PBS to remove the excess DiO. The labeled microbubbles 
were detected under an inverted fluorescence microscope 
(TE-2000U; Nikon, Tokyo, Japan). Five hundred microliters of 
microbubble solution was diluted into 1 mL deionized water, 
and then the size distribution of microbubbles was determined 
using a Zetasizer Nano ZS (Malvern Instruments, Malvern, 
UK) according to the manufacturer’s operating manual.
To quantify the anti-VCAM-1 antibody coverage, 
microbubbles were linked to PE-labeled streptavidin. Vari-
ous concentrations of PE-streptavidin ranging from 0.02 µg 
to 0.6 µg/100 µL microbubble suspension (approximately 
1 × 108) in PBS were used, and incubated for 60 minutes 
at room temperature. The unbound PE-streptavidin was 
removed by static flotation with triple washing in PBS, and 
the fluorescence intensity was detected by spectrofluoro-
photometry (RF-7000; Shimadzu, Kyoto, Japan). It was 
recognized that one streptavidin will bind one biotinylated 
anti-VCAM-1 monoclonal antibody, and the antibody cover-
age percentage (ie, antibody surface density) could be evalu-
ated using a standard curve of PE-streptavidin fluorescence 
intensity under various PE-streptavidin concentrations.
cell culture and activation
HUVEC-CS cells, a subline of human umbilical vein endothe-
lial cells (HUVEC),15 were obtained from the American Type 
Culture Collection (Manassas, VA), and cultured in a medium 
consisting of cell culture medium RPMI1640 supplemented 
with 10% NCS and 1% penicillin/streptomycin. Cells were 
maintained in an incubator at 37°C with 95% humidity and 
5% CO2. HUVEC-CS cells were subcultured after trypsiniza-
tion (0.025% trypsin, 0.5 mM EDTA, 1 mM sodium pyru-
vate and 10 mM HEPES) and grown to approximately 90% 
confluence. HUVEC-CS cells were subcultured into 12-well 
plates at a cell density of 4 × 104/mL, and maintained in an 
incubator overnight. The cultured HUVEC-CS cells were 
stimulated with 1 µg/mL LPS for 5 hours.
Animals
The animal protocol was approved by the Animal Care and 
Use Committee at the University of Electronic Science and 
  Technology of China. Sprague-Dawley (SD) rats were obtained 
from the Animal Center of Sichuan University (Chengdu, 
China). We established and characterized the SD rat atheroscle-
rosis model in our laboratory. Rats were split into two groups: 
one group receiving a high fat diet with vitamin D3, and the 
other (control) group receiving normal feed. After more than 
3 months, the animals were sacrificed. The aorta thoracalis was 
removed for paraffin sectioning and immunohistochemistry.
Immunohistochemistry
Staining was performed on perfusion-fixed and paraffin-
embedded sections. Tissue samples were fixed in cold 4% 
paraformaldehyde for more than 24 hours, and embedded 
in paraffin for sectioning. Paraffin sections from all animal 
groups were processed by staining with hematoxylin and 
eosin (H&E). For immunohistochemistry, 4 µm sections 
were cut, and an antigen retrieval protocol was performed. 
Endogenous peroxidase was eliminated using 3% hydrogen 
peroxide in distilled water. The sections were incubated with 
blocking reagents, a polyclonal rabbit anti-rat VCAM-1 pri-
mary antibody, biotinylated anti-rabbit secondary antibody, 
streptavidin-horseradish peroxidase (HRP) conjugate, and 
3,3′-diaminobenzidine (DAB) chromagen. The samples 
were examined under a microscope (TE-2000U; Nikon, 
Tokyo, Japan).
semi-quantitative rT-Pcr
Total RNA was isolated from cultured HUVEC-CS cells 
using TriZol reagent (Invitrogen, Carlsbad, CA) according 
to the manufacturer’s instructions. Primer sequences for 
VCAM-1 were 5′-ATGACATGCTTGAGCCAGG-3′ and 
5′-GTGTCTCCTTCTTT GACACT-3′ for the sense and 
antisense primers, respectively.16 One microgram of total 
RNA obtained from each sample was used for reverse tran-
scription-PCR (RT-PCR) in a 20 µL reaction mixture, and the 
reverse transcription was performed at 42°C for 90 minutes. 
The reverse transcriptase was inactivated at 70°C for 15 min-
utes. Three microliters of cDNA was amplified in a 25 µL 
standard PCR reaction. PCR amplification was performed 
on a thermal cycler over 35 cycles, each cycle consisting 
of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 
1 minute. Aliquots of the PCR reaction products were run on 
1.5% agarose gel electrophoresis and analyzed by product 
size, compared with a co-amplified control template.
Flow cytometric determination  
of VcAM-1 expression
Trypsinized HUVECS-CS cells were diluted slightly in 
PBS and incubated with anti-human VCAM-1 monoclonal 
antibody at 1:5 dilution for 30 minutes. The cells were then 
washed with PBS, and fixed in 4% paraformaldehyde. Flow 
cytometry (BD FACScanto II; BD Biosciences, Franklin International Journal of Nanomedicine 2011:6
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Figure 2 VcAM-1 expression on hUVec-cs cells or primary hUVecs. (A) mrNA 
expression of VcAM-1 on hUVec-cs cells activated by lipopolysaccharides (LPs). 
(B) The dark yellow shows VcAM-1 expression on hUVec-cs cells detected by 
immunocytochemistry. (C) Flow cytometric data using cultured hUVec-cs cells 
and  primary  hUVecs  with  Pe-labeled  VcAM-1.  The  cells  were  either  normal 
(control) or activated by LPs (1 µg/mL) for 5 hours.
Abbreviations: VcAM-1, vascular cell adhesion molecule 1; hUVec-cs, human 
umbilical vein endothelial cells, subline; hUVec, human umbilical vein endothelial 
cells; LPs, lipopolysaccharides; Pe, phycoerythrin.
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Lakes, NJ) were used to quantify VCAM-1 expression on 
the surfaces of HUVECS-CS cells and primary HUVECs 
(n = 3 per condition).
Shear flow simulation and microbubble  
adhesion
A rectangular parallel plate perfusion chamber, designed by our 
laboratory, was used to examine adhesion of microbubbles to 
cultured HUVEC-CS monolayer under shear flow conditions.13 
This system comprises a transparent polymethylmethacrylate 
plate, two silastic rubber gaskets, and a standard glass cover-
slip. The coverslip with a near 90% confluent monolayer of 
HUVEC-CS was mounted over the groove with the cells facing 
the inside, and an approximately 500 µm gap was formed over 
the HUVEC-CS cells. The wall shear stress (τw) is related to 
the volumetric flow rate (Q) by τw = 6µQ/w(h)2, where µ is 
the fluid viscosity, w is the width of the flow field, and h is 
the height. The shear stress can be regulated through the flow 
rate, Q. The chamber was placed on the stage of an inverted 
microscope (TE-2000U; Nikon, Tokyo, Japan).
HUVEC-CS cells were pre-seeded on a coverslip for 
48 hours. The cells were activated by LPS stimulation for 
5 hours, and the cultured HUVEC-CS cells coverslip was 
fixed in the flow chamber for continuous shear stress expo-
sure (6.3 or 10.4 dynes/cm2, 3 minutes). Before perfusion 
the microbubble suspension was mixed with the perfusion 
medium. Adhesion was evaluated by counting the adhered 
microbubble numbers under a microscope. Six random fields 
(magnification 40×) were chosen to count the microbubbles 
retained on the endothelial cell monolayer.
statistical analysis
Results are expressed as arithmetic mean ± SEM. Student’s t-test 
was used to calculate the statistical significance.   Differences 
between multiple groups were examined using ANOVA (Bon-
ferroni t-test). Mean differences with a P value less than 0.05 
were considered to be significant. Statistical analyses were 
performed using SPSS software (SPSS Inc, Chicago, IL).
Results
VcAM-1 expression by rT-Pcr,  
immunohistochemistry, and flow  
cytometry
VCAM-1 expression was detected by RT-PCR. It was found 
that VCAM-1 was unregulated after LPS stimulation, and 
mRNA expression presented in a dose-dependent manner as 
shown in Figure 2A. Furthermore, VCAM-1 immunoreactiv-
ity was observed both in normal cultured HUVEC-CS cells 
(control) and LPS-activated HUVEC-CS cells (Figure 2B). 
VCAM-1 expression in LPS-activated HUVEC-CS cells 
was obviously increased when compared with the control. 
It has been reported that other inflammatory cytokines 
could also upregulate the expression of some specific adhe-
sion molecules in endothelial cells.17–19 To further confirm 
VCAM-1 expression quantitatively, we investigated LPS-in-
duced VCAM-1 expression in HUVEC-CS cells and primary 
HUVECs. LPS-induced VCAM-1 expression in HUVEC-CS 
cells and primary HUVECs were both significantly higher 
than the control   (Figure 2C). Immunohistochemical analysis 
also showed higher levels of VCAM-1 circumscribing the 
aorta thoracalis compared with controls (Figure 3), suggest-
ing that the increased expression of VCAM-1 was partly 
due to increased expression of VCAM-1 on the vascular 
endothelial cells.International Journal of Nanomedicine 2011:6
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Figure 3 (A) example of hematoxylin and eosin (h&e) staining of aortic morphology 
of normal (left) and atherosclerotic sD rats (right). (B) Overexpression of VcAM-1 
(white arrow) on the atherosclerotic lesion detected by immunohistochemistry.
Abbreviations: h&e, hematoxylin and eosin; sD, sprague-Dawley; VcAM-1, vascular 
cell adhesion molecule 1.
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Figure  4  characterization  of  synthesized  microbubbles.  (A)  representative 
bright  field  micrograph.  (B)  Representative  fluorescent  micrograph  with  DiO 
labeling. (C) size distribution of microbubbles measured with a Zetasizer Nano Zs, 
confirming the mean diameter of the microbubbles to be 3.57 µm.
Abbreviation: DiO, 3,3′-dioctadecyloxacarbocyanine perchlorate.
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Figure 5 The fluorescence intensity of PE-streptavidin conjugated to microbubbles 
detected by spectrofluorophotometry. Biotinylated microbubbles were incubated 
with various concentrations of Pe-streptavidin.
Abbreviation: Pe, phycoerythrin.
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  anti-VCAM-1 monoclonal antibody coverage percentages 
were divided into five groups of 0% (control), 22.2%, 32.2%, 
63.3%, and 100%. The adhesion data from coverslips of 
HUVEC-CS cells perfused with targeted microbubbles 
(conjugated anti-VCAM-1 monoclonal antibodies), control 
characterization of microbubbles  
and VCAM-1 conjugation
Figures 4A and B show the bright field and fluorescent micro-
scopic morphology of synthesized microbubbles, respectively. 
The prepared microbubbles are smooth and spherical. Our 
data also showed that the size of microbubbles mainly lies 
in the range of 2 to 5 µm (Figure 4C), with a mean diameter 
of ∼3.57 µm. Statistical analysis showed that nearly 80% of 
microbubbles had diameters below 5.5 µm (data not shown).
The fluorescence intensity data (relative fluorescence 
unit, RFU) from microbubbles incubated with various con-
centrations of PE-streptavidin (0.02–1 µg/mL) are shown in 
Figure 5. The conjugated PE-streptavidin densities on the 
microbubbles show a sigmoid distribution, and the conjugated 
PE-streptavidin mount reaches a saturation state when the PE-
streptavidin concentration exceeds 0.6 µg/mL. It is reasonable 
to assume that one streptavidin will bind one biotinylated anti-
VCAM-1 monoclonal antibody. Consequently, the antibody 
coverage percentage can be calculated through the fluores-
cence intensity of PE-streptavidin using a standard curve of 
PE-streptavidin fluorescent intensities and concentrations 
(data not shown). Based on this assumption, the anti-VCAM-1 
antibody densities (coverage percentages) have a linear rela-
tionship to the PE-streptavidin concentration, but achieve a 
maximum (100% coverage percentage) (Figure 6).
Microbubble adhesion to endothelial  
cells under shear stress
Microbubble adhesion was studied under several sets 
of flow and antigen surface density conditions. The International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2048
Yang et al
microbubbles (no conjugated anit-VCAM-1) and isotype 
control microbubbles (conjugated nonspecific IgG) are 
shown in Figures 7 and 8. The adhered microbubble num-
ber on the HUVEC-CS cell monolayer was quantified by 
microbubble counting from six random microscopic fields 
for each group (magnification 40×) (Figures 7B and 8B). 
Among the microbubbles targeted to VCAM-1, adhesion 
increased with increasing anti-VCAM-1 coverage percentage 
for LPS-activated HUVEC-CS cells. Adherence of VCAM-
1-targeted microbubbles was greater for LPS-activated than 
normal HUVEC-CS cells, and increased with increasing 
anti-VCAM-1 coverage percentage. There was a signifi-
cant difference between the targeted microbubble groups 
  (22.2%, 32.2%, 63.3%, and 100%) and the control microbub-
ble group or the isotype control microbubble group.
By comparing Figures 7 and 8, the adhesion of microbub-
bles for each group also shows a shear-dependent relation-
ship. Microbubble adhesion significantly decreased when the 
exposed shear stresses increased from 6.3 to 10.4 dynes/cm2, 
which demonstrated that the interaction of microbubbles with 
HUVEC-CS cells depends on both bound antibody densities 
and flow conditions.
Discussion
Microbubbles are very effective at augmenting contrast in ultra-
sound images of the vasculature and enhancing   visualization 
of the vasculature throughout the body and within organs. The 
advantages of using microbubbles for this purpose are that 
they are biocompatible, stable, small enough to travel through 
the entire vasculature, and highly echogenic.4,20,21
In this study, we developed and described a new type 
of bio-functionalized microbubbles, VCAM-1-targeted 
microbubbles, which selectively accumulate and adhere to 
inflamed endothelial cells in vitro under hemodynamic shear 
flow simulation conditions. In our previous work, we dem-
onstrated that LPS-induced expressions of proinflammatory 
cytokines (IL-1β, IL-6) and chemokines (IL-8, MCP-1) were 
greatly upregulated.22 LPS is a potent activator of cells in the 
immune and inflammatory systems, including macrophages, 
monocytes, and endothelial cells. In this study, we identi-
fied whether VCAM-1 expression in endothelial cells was 
also upregulated by LPS stimulation. The data presented 
in Figure 1 strongly indicates that VCAM-1 expression 
in LPS-activated HUVEC-CS cells is significantly higher 
compared to that of the control (non-LPS treated cells). LPS 
could activate endothelial cells through the nuclear factor-κB 
pathway, and lead to expression of its targeted genes, includ-
ing VCAM-1.22
Atherosclerosis is a chronic vascular inflammation in its 
early stages. To verify whether VCAM-1 expression in vivo 
was similar to that in atherosclerogenesis, we constructed a 
rat model of atherosclerosis, and detected VCAM-1 expres-
sion in the endothelium. The in vivo results are consistent 
with the in vitro data, which suggests that VCAM-1 is an 
ideal target or biomarker for microbubble delivery (Figure 3). 
Based on these findings, we designed targeted microbubbles 
to conjugate the ligand of VCAM-1 (anti-VCAM-1 mono-
clonal antibody) in this study.
There are many factors affecting targeted microbubble 
adhesion to the surfaces of endothelial cells. Two important 
factors amongst them are the antibody coverage percentages 
on the microbubbles (ie, antibody surface densities) and 
the exposed shear stresses. Our data showed that antibody 
coverage percentages were positively related to microbub-
ble adhesion number under both low (6.3 dynes/cm2) and 
high shear stress (10.4 dynes/cm2) conditions. In other 
words, the level of microbubble adhesion increased with 
the antibody coverage percentages on the microbubbles. 
Furthermore, we found that nontargeted microbubbles 
(bare microbubbles) exhibited a very low adhesion to 
HUVEC-CS cells. Similar results were obtained for nonspe-
cific IgG conjugated microbubbles (isotype control). The 
study also showed that the high adherence of anti-VCAM-1 
antibody conjugated microbubbles to LPS-  activated 
endothelial cells was specific. Our data showed that anti-
body coverage percentages on the microbubbles should 
be as high as possible in order to increase the numbers of 
adhered microbubbles.
0
0 0.02 0.04 0.06
PE-streptavidin (µg/mL)
A
n
t
i
-
V
C
A
M
-
1
 
c
o
v
e
r
a
g
e
 
p
e
r
c
e
n
t
a
g
e
 
(
%
)
0.08 0.1
20
40
60
80
100
120
Figure 6 The calculated anti-VcAM-1 coverage percentages (antibody densities) on 
microbubble surface under various concentrations of Pe-streptavidin. The antibody 
coverage percentages could be evaluated through a standard curve of Pe-streptavidin 
fluorescent intensity under various concentrations of PE-streptavidin.
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Figure 7 Adhesion of control microbubbles, VcAM-1-targeted microbubbles, and isotype control Igg microbubbles under low shear stress exposure of 6.3 dynes/cm2 for 
3 minutes. (A) Representative bright field micrographs of microbubbles adhered to LPS-activated HUVEC-CS cells (magnification 40×). The insets are the high-magnification 
fields of the white dotted windows. (B) The adhered microbubble numbers on the HUVEC-CS cell monolayer were quantified by microbubble counting from six random 
microscopic fields (magnification 40×) for each group.
Notes: *P , 0.05 vs control (non-targeted microbubbles); **P , 0.01 vs control (non-targeted microbubbles) or non-specific IgG conjugated microbubbles.
Abbreviations: VcAM-1, vascular cell adhesion molecule  1; hUVec-cs, human umbilical vein endothelial cells, subline.
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Comparing the adhered number of targeted microbub-
bles under the two shear stress conditions, it was found that 
the adhered microbubble numbers decreased at the same 
antibody coverage percentage on the microbubble surfaces 
under high shear stress (Figures 7 and 8). Antibody-ligand 
binding may have been more easily broken under exposure 
to higher shear stress conditions, but adhesion was still 
significantly higher than in the controls. This specific 
adhesion could be used in clinical applications for targeted 
ultrasound molecular imaging and ultrasound-assisted 
drug/gene delivery to localized disease sites in the future. 
In the present study, avidin–biotin chemistry was chosen 
to couple the biotinylated microbubbles with biotinylated 
antibodies. Recently, a new protocol introduced superpara-
magnetic iron oxide nanoparticles (mean diameter 12 nm) 
into the polymer shell of the microbubbles.23 This suggests 
that dual-targeted microbubbles with magnetic and ligand 
targets could be prepared, and that microbubble accumu-
lation at disease sites could be enhanced using external 
magnetic fields.International Journal of Nanomedicine 2011:6
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Figure 8 Adhesion of control microbubbles, targeted microbubbles, and isotype control Igg microbubbles under high shear stress exposure of 10.4 dynes/cm2 for 3 minutes. 
(A) Representative bright field micrographs of microbubbles adhered to LPS-activated HUVEC-CS cells (magnification 40×). The insets are the high-magnification fields of the 
white dotted windows. (B) The adhered microbubble numbers on the HUVEC-CS cell monolayer were quantified by microbubble counting from six random microscopic 
fields (magnification 40×) for each group.
Notes: *P , 0.05 versus control (non-targeted microbubbles); **P , 0.01 versus control (non-targeted microbubbles) or non-specific IgG conjugated microbubbles.
Abbreviations: LPs, lipopolysaccharide; hUVec-cs, human umbilical vein endothelial cells, subline.
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Conclusion
In summary, we have engineered a novel type of bio-
functionalized ultrasound microbubbles (VCAM-1-targeted 
microbubbles) with an average diameter of 3.57 µm using 
multi-step biotin–avidin bridging chemistry methods. The 
targeted microbubbles can specifically adhere to inflam-
matory endothelial cells activated by LPS, and their adher-
ence depends on the antibody coverage percentages on the 
microbubbles and hemodynamic shear flow conditions. 
The bio-functionalized microbubbles have promising appli-
cations in targeted ultrasound molecular imaging and targeted 
ultrasound-assisted drug delivery in the future.
Acknowledgments
We would like to acknowledge financial support from the 
National Natural Science Foundation of China (30700151, 
81071257), New Century Excellent Talents Program in 
  Chinese Universities (NCET-09-0263), Sichuan Youth International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
2051
Adhesion of ultrasound microbubbles to endothelial cells
  Science and Technology Foundation of China (2010 JQ0004), 
Fundamental Research Funds for Central Universities 
(23801135, 23801131), and Visiting Scholar Foundation 
of Key Lab of Biorheological Science and Technology in 
Chongqing University, Ministry of Education, China.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Lindner JR. Microbubbles in medical imaging: current applications and 
future directions. Nat Rev Drug Discov. 2004;3(6):527–532.
  2.  Sirsi S, Borden M. Microbubble compositions, properties and biomedi-
cal applications. Bubble Sci Eng Technol. 2009;1(1–2):3–17.
  3.  Takalkar AM, Klibanov AL, Rychak JJ, Lindner JR, Ley K. Binding 
and detachment dynamics of microbubbles targeted to P-selectin under 
controlled shear flow. J Control Release. 2004;96(3):473–482.
  4.  Weller GE, Villanueva FS, Klibanov AL, Wagner WR. Modulating 
targeted adhesion of an ultrasound contrast agent to dysfunctional 
endothelium. Ann Biomed Eng. 2002;30(8):1012–1019.
  5.  Liu Y, Miyoshi H, Nakamura M. Encapsulated ultrasound microbubbles: 
therapeutic application in drug/gene delivery. J Control Release. 
2006;114(1):89–99.
  6.  Liu Y, Uno H, Takatsuki H, Hirano M, Sakanishi A. Interrelation 
between HeLa-S3 cell transfection and hemolysis in red blood cell sus-
pension using pulsed ultrasound of various duty cycles. Eur Biophys J. 
2005;34(2):163–169.
  7.  Liu Y, Yang H, Sakanishi A. Ultrasound: mechanical gene transfer into 
plant cells by sonoporation. Biotechnol Adv. 2006;24(1):1–16.
  8.  Sakhalkar HS, Hanes J, Fu J, et al. Enhanced adhesion of ligand-
conjugated biodegradable particles to colitic venules. FASEB J. 2005; 
19(7):792–794.
  9.  Allen AR, McHale J, Smith J, et al. Endothelial expression of 
VCAM-1 in experimental crescentic nephritis and effect of antibodies 
to very late antigen-4 or VCAM-1 on glomerular injury. J Immunol. 
1999;162(9):5519–5527.
  10.  Fruebis J, Silvestre M, Shelton D, Napoli C, Palinski W. Inhibition of 
VCAM-1 expression in the arterial wall is shared by structurally dif-
ferent antioxidants that reduce early atherosclerosis in NZW rabbits. 
J Lipid Res. 1999;40(11):1958–1966.
  11.  Lei X, Lawrence MB, Dong C. Influence of cell deformation on leu-
kocyte rolling adhesion in shear flow. J Biomech Eng. 1999;121(6): 
636–643.
  12.  Liang S, Dong C. Integrin VLA-4 enhances sialyl-Lewisx/a-negative 
melanoma adhesion to and extravasation through the endothe-
lium under low flow conditions. Am J Physiol Cell Physiol. 2008; 
295(3):C701–C707.
  13.  Liu Y, Zhao F, Gu W, et al. The roles of platelet GPIIb/IIIa and alphav-
beta3 integrins during HeLa cells adhesion, migration, and invasion to 
monolayer endothelium under static and dynamic shear flow. J Biomed 
Biotechnol. 2009;2009:829243.
  14.  Kaufmann BA, Lewis C, Xie A, Mirza-Mohd A, Lindner JR. 
Detection of recent myocardial ischaemia by molecular imaging of 
P-selectin with targeted contrast echocardiography. Eur Heart J. 
2007;28(16):2011–2017.
  15.  Gifford SM, Grummer MA, Pierre SA, et al. Functional characterization 
of HUVEC-CS: Ca2+ signaling, ERK 1/2 activation, mitogenesis and 
vasodilator production. J Endocrinol. 2004;182(3):485–499.
  16.  Kaplanski G, Marin V, Fabrigoule M, et al. Thrombin-activated 
human endothelial cells support monocyte adhesion in vitro follow-
ing expression of intercellular adhesion molecule-1 (ICAM-1; CD54) 
and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood. 
1998;92(4):1259–1267.
  17.  Sawa Y, Ueki T, Hata M, et al. LPS-induced IL-6, IL-8, VCAM-1, and 
ICAM-1 expression in human lymphatic endothelium. J Histochem 
Cytochem. 2008;56(2):97–109.
  18.  Shi Q, Wang J, Wang XL, et al. Comparative analysis of vascular 
endothelial cell activation by TNF-alpha and LPS in humans and 
baboons. Cell Biochem Biophys. 2004;40(3):289–303.
  19.  Zeuke S, Ulmer AJ, Kusumoto S, Katus HA, Heine H. TLR4-mediated 
inflammatory activation of human coronary artery endothelial cells by 
LPS. Cardiovasc Res. 2002;56(1):126–134.
  20.  Rychak JJ, Lindner JR, Ley K, Klibanov AL. Deformable gas-
filled microbubbles targeted to P-selectin. J Control Release. 2006; 
114(3):288–299.
  21.  Villanueva FS, Jankowski RJ, Klibanov S, et al. Microbubbles targeted 
to intercellular adhesion molecule-1 bind to activated coronary artery 
endothelial cells. Circulation. 1998;98(1):1–5.
  22.  Meng Q, Liu Y, Lou C, et al. Emodin suppresses LPS-induced 
proinflammatory responses and NF-κB activation by disruption 
of lipid rafts in CD14 negative endothelial cells. Br J Pharmacol. 
2010;161(7):1628–1644.
  23.  Yang F, Li Y, Chen Z, Zhang Y, Wu J, Gu N. Superparamagnetic 
iron oxide nanoparticle-embedded encapsulated microbubbles as 
dual contrast agents of magnetic resonance and ultrasound imaging. 
  Biomaterials. 2009;30(23–24):3882–3890.